Browse Pharmaceutical industry topic

Physiological aspects subtopic

Articles 1-48 out of 48 article(s) Title Author Type Date Words The Merck manual of patient symptoms; a concise, practical guide to etiology, evaluation, and treatment. Book review Dec 1, 2009 121 Natural therapeutics: calorie restriction mimetics. Holt, Stephen Report Oct 1, 2009 3572 Concert Pharmaceuticals Presents Clinical Results Demonstrating Reduced Drug-Drug Interactions with a Deuterium-Modified Compound. Sep 14, 2009 687 India : Neuland commences peptides production. Aug 29, 2009 122 Artificial liver, skin, intestine to revolutionise drug trials. Jun 26, 2009 411 Agios Pharmaceuticals' Focus of Drug Research - Cancer Metabolism - Selected for Stand Up To Cancer Grant. May 28, 2009 684 Celsius Now Available in Roche Bros. Supermarkets Throughout Massachusetts. May 28, 2009 441 Agios Pharmaceuticals' Founders Author Science Review on Cancer Metabolism. May 21, 2009 759 Agios Pharmaceuticals Highlights Extensive Cancer Metabolism Research at AACR. Apr 30, 2009 644 Research and Markets: Merck Serono S.A. - Strategic Analysis Review - Available Now. Company overview Apr 20, 2009 317 Research and Markets: Mass Spectrometry in Drug Metabolism and Pharmacokinetics. Mar 23, 2009 402 Agios Pharmaceuticals Appoints Charles Sawyers, M.D., to Scientific Advisory Board. Feb 6, 2009 622 Research and Markets: Educational Review Manual for Endocrinology, Diabetes, and Metabolism with More Unique Focus on Diabetes. Jan 22, 2009 279 Research and Markets: Educational Review Manual in Endocrinology, Diabetes, and Metabolism is an Influencing Review of the Subject by Leading Practitioners in the Field. Jan 16, 2009 273 Research and Markets: Exciting Book Discusses the Modern Application of Biocatalysis in Discovery, Development and Manufacturing in the Pharmaceutical Industry. Nov 21, 2008 326 VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeting. Sep 28, 2008 1735 NPS Pharmaceuticals to Report GATTEX(TM) Data at ESPEN, ACG, UEGW Congresses. Clinical report Sep 11, 2008 823 Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration. Sep 4, 2008 839 Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular Degeneration. Aug 19, 2008 1393 Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University. Jul 1, 2008 1057 Elixir Pharmaceuticals Researchers Publish New Data Validating Ghrelin as a Key Metabolic Regulator. May 28, 2008 1318 OXiGENE Announces Preclinical Data Demonstrating that the Active Metabolite of ZYBRESTAT Improves Glucose Metabolism through Similar Mechanism as a Sirtuin Agonist. Apr 30, 2008 661 Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration. Apr 28, 2008 1736 PhiloGene Inc. Announces Revolutionary Advances in the Treatment of Cancer and Macular Degeneration. Apr 22, 2008 974 Elixir Pharmaceuticals Presents New Data on Ghrelin Inhibition at Keystone Meeting. Feb 22, 2008 642 G Protein Coupled Receptors Molecular Pharmacology Offers a Unique View of Academic and Applied Approaches to Pharmaceutical Research. Nov 22, 2007 363 Merck's Investigational CETP-Inhibitor, MK-0859 (anacetrapib), Produced Positive Effects on Lipids with No Observed Blood Pressure Changes in Phase IIb Study. Oct 4, 2007 944 Regeneron Announces Positive Primary Endpoint Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration. Oct 1, 2007 1410 National Baby Boomer Pain Poll Reports: '50 is the New 40,' but Can the Body Keep Moving? Sep 28, 2007 958 Regeneron and Bayer HealthCare Initiate Phase 3 Global Development Program For VEGF Trap-Eye In Wet Age-Related Macular Degeneration (AMD). Aug 3, 2007 1450 Insight into the Pipeline Status of Macular Degeneration Drugs. Jul 13, 2007 303 OXiGENE Announces a Poster Presentation Highlighting Results from its Study of ZYBRETSTAT(TM) CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology. May 7, 2007 586 Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration. Clinical report Mar 27, 2007 1331 OXiGENE Announces Positive Results from its Phase II CA4P Clinical Trial in Myopic Macular Degeneration (MMD-213). Feb 15, 2007 695 AXM Pharma Appointed Exclusive Sales and Marketing Agent for Leading Pharmaceutical Product. Feb 8, 2007 442 Sirtris Pharmaceuticals: Resveratrol Reduces Fat and Boosts Endurance by Activation of SIRT1, First Aging Gene Shown to Accelerate Human Metabolism. Nov 16, 2006 830 OXiGENE to Focus Ophthalmology Strategy Toward Non-Invasive Administration of CA4P for Age-Related Macular Degeneration (AMD); Closes Enrollment of Phase II CA4P Clinical Trial in Myopic Macular Degeneration (MMD-213). Sep 12, 2006 802 As part of a collaboration agreement with Applied Biosystems, SAIC-Frederick's Core Genotyping Facility will use more than 2,400 of the company's TaqMan Drug Metabolism Genotyping Assays. Jul 15, 2006 37 OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib sodium injection) Maintenance Trial in Neovascular Age-Related Macular Degeneration (AMD). Jun 26, 2006 1694 Othera Pharmaceuticals and the National Eye Institute Collaborate in Dry AMD Study; A Phase II Study of OT-551 Antioxidant Eye Drop in Participants with Bilateral Geographic Atrophy Associated with Age-Related Macular Degeneration. Apr 5, 2006 387 OSI Pharmaceuticals Announces European Regulatory Approval for Macugen(R) (pegaptanib sodium injection); First Treatment for Neovascular (Wet) Age-related Macular Degeneration (AMD) That Targets Underlying Disease Process. Feb 2, 2006 1105 Patients Lose Fat and Improve Health with Therapeutic Lifestyle Changes (TLC) from Metagenics; Winners of 3rd Annual Get Healthy! Get Lean! Challenge(TM) Lost 10% Body Fat in 12-Week Period. Jan 5, 2006 1093 FDA ACCEPTS ENTREMED IND FOR ENMD-1198 ANTITUMOR AGENT. Jan 1, 2006 666 BARRIER REPORTS POSITIVE PHASE 2A DATA FOR ORAL RAMBAZOLE. Nov 1, 2005 746 Pharmacopeia forms macular degeneration agreement with Allergan. Jun 1, 2005 370 Bionomics files further patents for BNO69 cancer target. May 1, 2005 347 Genaissance allowed patent for method of testing individuals for genetic predisposition to reduced metabolism of drugs. Mar 1, 2005 473 Alternative therapies for the holistic care of the HIV/AIDS patient. Bodkin, Candice Sep 1, 2003 5995